Summary of previous studies that have examined the effect of EBV status on clinical outcome in Hodgkin lymphoma
Reference . | Population-based . | No. of Patients . | Age range, y . | Median follow-up, mo . | NLPHL included . | %EBV-associated . | Prognostic significance of EBV-association on OS . |
|---|---|---|---|---|---|---|---|
| Armstrong et al5 | No | 59 | Not stated | Not stated | Yes | 36 | None |
| Axdorph et al6 | No | 95 | 14-77 | 145 | No | 33 | None |
| Enblad et al11 | Yes | 117 | 11-87 | 130 | Yes | 27 | None |
| Flavell et al8 | No | 273 | ≥15 | 60 | Yes | 29 | None |
| Murray et al7 | No | 190 | 22-49 | 86 | Yes | 27 | None |
| Vestlev et al4 | No | 66 | 9-78 | 22 | Yes | 41 | None |
| Krugmann et al9 | No | 119 | 14-83 | 122 | No | 26 | None |
| Herling et al10 | No | 303 | Adults | 65 | No | 21 | None |
| Vassalo et al15 | No | 78 | 15-75 | Not stated | No | 64 | Favorable (assessed by LMP1 expression) |
| Glavina-Durdov et al16 | No | 100 | 13-84 | 60 | Yes | 26 | None. Positive impact on DFS in those ≤30 y |
| Engel et al13 | No | 47 | ≤14 | Not stated | No | 68 | Favorable |
| Morente et al12 | No | 140 | 5-83 | >24 | Yes | 51 | Favorable |
| Naresh et al14 | No | 110 | 4-61 | 57 | No | 78 | Favorable |
| Stark et al18 | Yes | 102 | ≥60 | 62 | Yes | 34 | Unfavorable |
| Clarke et al17 | Yes | 311 | 19-79 | 73 | Yes | 17 | Unfavorable in those ≥45 y |
Reference . | Population-based . | No. of Patients . | Age range, y . | Median follow-up, mo . | NLPHL included . | %EBV-associated . | Prognostic significance of EBV-association on OS . |
|---|---|---|---|---|---|---|---|
| Armstrong et al5 | No | 59 | Not stated | Not stated | Yes | 36 | None |
| Axdorph et al6 | No | 95 | 14-77 | 145 | No | 33 | None |
| Enblad et al11 | Yes | 117 | 11-87 | 130 | Yes | 27 | None |
| Flavell et al8 | No | 273 | ≥15 | 60 | Yes | 29 | None |
| Murray et al7 | No | 190 | 22-49 | 86 | Yes | 27 | None |
| Vestlev et al4 | No | 66 | 9-78 | 22 | Yes | 41 | None |
| Krugmann et al9 | No | 119 | 14-83 | 122 | No | 26 | None |
| Herling et al10 | No | 303 | Adults | 65 | No | 21 | None |
| Vassalo et al15 | No | 78 | 15-75 | Not stated | No | 64 | Favorable (assessed by LMP1 expression) |
| Glavina-Durdov et al16 | No | 100 | 13-84 | 60 | Yes | 26 | None. Positive impact on DFS in those ≤30 y |
| Engel et al13 | No | 47 | ≤14 | Not stated | No | 68 | Favorable |
| Morente et al12 | No | 140 | 5-83 | >24 | Yes | 51 | Favorable |
| Naresh et al14 | No | 110 | 4-61 | 57 | No | 78 | Favorable |
| Stark et al18 | Yes | 102 | ≥60 | 62 | Yes | 34 | Unfavorable |
| Clarke et al17 | Yes | 311 | 19-79 | 73 | Yes | 17 | Unfavorable in those ≥45 y |
NLPHL indicates nodular lymphocyte predominant Hodgkin lymphoma; EBV, Epstein Barr virus; OS, overall survival; LMP1, Epstein-Barr virus latent membrane protein 1; and DFS, disease-free survival.